Scinus Secures €3 Million Strategic Investment to Accelerate Global Roll-Out of the Osilaris™ Cell Expansion Platform 

Scinus Group today announced the successful closing of a €3 million strategic investment round led by Myosotis Investments, founded by biotech entrepreneur Wietse Mulder. Existing shareholders, including the company’s founders and the Demcon Innovation Fund, also participated in the round. 

The investment marks an important milestone in Scinus’ development and will support the accelerated commercial roll-out of the Osilaris™ Platform in key markets, while further strengthening the company’s governance and operational maturity. 

Following the closing of the round, Dr. Erik Vossenaar, currently acting as Managing Director of Scinus, will be appointed Executive Director and CEO. Dr. Janeska de Jonge will join the Board as Non-Executive Director, representing Myosotis Investments. A third board member will be appointed at a later stage.

Addressing the Manufacturing Challenge in Cell Therapy 

The promise of cell therapies is increasingly evident, yet manufacturing remains one of the industry’s most significant hurdles. As more therapies advance beyond early clinical stages, the ability to reliably expand cells at scale - without escalating costs - is becoming essential. Scalable, automated and closed manufacturing platforms are critical to enabling broader patient access and sustainable commercialization. 

Scinus has developed the Osilaris™ Platform, a closed and automated bioreactor system designed specifically to address these challenges. Osilaris enables cell cultures to expand dynamically as the cell population grows, avoiding the constraints of fixed-volume systems and supporting significantly higher expansion rates. At the same time, its proprietary oxygenation and mixing approach allows gentle, shear-free processing while maintaining tight control over critical process parameters, particularly important for sensitive cell types. 

By combining scalability with improved environmental control, the Osilaris™ bioreactor platform supports more consistent manufacturing outcomes while reducing operational complexity. The fully closed and GMP-compliant system allows integration of multiple unit operations within a single environment, lowering contamination risk, reducing manual handling steps, and decreasing GMP media consumption and labor requirements. 

The platform is commercially available and installed at leading academic ATMP manufacturers as well as multiple ATMP CDMOs in Europe, including globally recognized players. It supports a broad range of applications, including CAR-T and CAR-TCR therapies, TILs, MSCs, iPSCs, organoids, viral vector production and extracellular vesicles. 

Strategic Investor with Operational Expertise 

Dr. Wietse Mulder, Founder and Managing Partner of Myosotis Investments commented: “Advanced cell therapies require robust and scalable manufacturing solutions. Scinus has developed a differentiated platform that addresses key bottlenecks in control, scalability and cost-efficiency. I am impressed by the technological foundation of Osilaris and the team’s disciplined execution focus. We look forward to supporting Scinus in its next phase of commercial growth.” 

Dr. Dennis Schipper, Founder and CEO of Demcon, added: “Within the Demcon group, we have worked closely with Scinus to industrialize its cell expansion technology into a robust platform for cellular biotherapy manufacturing. It is rewarding to see Scinus reach this level of maturity, and we are pleased that the company is now ready to move decisively into its next phase of growth.” 

Dr. Erik Vossenaar, incoming CEO of Scinus, stated: “We are pleased to welcome Myosotis Investments as lead investor in this round and to continue the strong support from our founders and Demcon. This investment brings Scinus to the next level of organizational maturity. With a strengthened governance structure and a market-ready GMP-compliant platform, we are well positioned to execute our commercial roll-out strategy in key markets and move steadily toward profitability.” 

-END-

More information:
Scinus Cell Expansion Netherlands B.V.
Utrechtseweg 48, 3704 HE, Zeist, The Netherlands
www.scinus.com | info@scinus.com

About Scinus Group 

Scinus Group was established in 2016 following its demerger from Xpand Biotechnology. Founded by Prof. Dr. Joost de Bruijn, Prof. Dr. Clemens van Blitterswijk, and FrankJan van der Velden, the company brings together deep scientific expertise in regenerative medicine with strong industrial and business leadership. In 2019, Demcon joined Scinus Group as a strategic investor and engineering partner. Under the leadership of Dr. Michiel Jannink, this partnership supported the further development, industrialization and market introduction of the Osilaris platform. Scinus Group comprises Scinus Holding B.V. and its wholly owned operating company, Scinus Cell Expansion Netherlands B.V., headquartered in Zeist, the Netherlands.

More information: info@scinus.com | www.scinus.com | LinkedIn

About Myosotis Investments B.V. 

Myosotis Investments was founded in 2024 by Dr. Wietse Mulder and is based in Zeist, The Netherlands. The firm supports organizations that have a mission-driven approach aiming to impact healthcare leading to better care of patients. The firm focuses on advancements in molecular diagnostics and life sciences. Their current portfolio includes innovative companies such as IDEVAX B.V., Kairos Biotech Ltd, Cyclomics B.V. and Tzu Cancer Therapeutics B.V. 

More information: www.myosotisinvestments.com | LinkedIn

About Demcon and Demcon Innovation Fund 

Demcon (1,100+ employees) develops, manufactures, and delivers technology and innovative products. The Demcon group has locations in Best, Delft, Enschede, Groningen, Leiden, Maastricht, Scheveningen, Münster (Germany), Tokyo (Japan), Singapore, and the USA. The company originated from the passion of the founders for combining creativity and technical expertise aimed at solving complex issues. These issues are technological and societal in nature and often have a direct or indirect influence on people and their environment. Whether it concerns medical solutions, systems that protect our safety or sustainable innovations in areas like water and energy, Demcon's contributions benefit current and future generations. In addition to developing technical solutions, Demcon focuses on stimulating entrepreneurship and investing in talent and education. 

More information: www.demcon.com | LinkedIn